(Circulation. 1997;96:1386-1389.)
© 1997 American Heart Association, Inc.
Articles |
by Human Mononuclear Cells
From the Department of Cardiovascular Medicine, Kyoto University, Japan.
Correspondence to Akira Matsumori, MD, PhD, Department of Cardiovascular Medicine, Kyoto University, 54 Kawaracho Shogoin, Sakyo-ku, Kyoto 606, Japan. E-mail amat{at}kuhp.kyoto-u.ac.jp
| Abstract |
|---|
|
|
|---|
and
interleukins (ILs) are capable of modulating
cardiovascular function and that drugs used in the
treatment of heart failure have various modulatory effects on the
production of cytokines. This study was performed to
examine the effects of amiodarone (a drug shown to be
beneficial in some patients suffering from heart failure) versus other
antiarrhythmic agents on the production of cytokines in
vitro.
Methods and Results Human peripheral blood
mononuclear cells (PBMC) were obtained from healthy volunteers. PBMC
were cultured with 0.1, 1, and 10 µmol/L of amiodarone,
quinidine, disopyramide, and lidocaine in the presence of
lipopolysaccharide. After 24 hours' incubation, TNF-
,
IL-1ß, and IL-6 were measured in the culture supernatants by an
enzyme-linked immunosorbent assay. TNF-
production was
inhibited by amiodarone but stimulated by quinidine in a
concentration-dependent manner. Disopyramide and lidocaine
tended to increase TNF-
production. IL-6 production
was decreased by amiodarone in all concentrations but was
increased significantly by disopyramide. Modulation of
IL-1ß production by amiodarone was biphasic and
significantly increased at a concentration of 10 µmol/L.
Conclusions These previously unrecognized immunomodulatory effects of amiodarone may contribute to its beneficial effects in heart failure patients.
Key Words: amiodarone heart failure immune system interleukins
| Introduction |
|---|
|
|
|---|
Recent studies from our laboratory have shown that drugs for heart failure modulate the production of cytokines in various ways9 10 11 and suggest that some of these immunomodulatory effects are relevant to the effects of drugs in heart failure patients. Accordingly, the present study was performed to investigate whether the positive hemodynamic effects of amiodarone might be attributable to a modulation of cytokine production.
| Methods |
|---|
|
|
|---|
, IL-1ß, and IL-6 levels in the
culture supernatants were determined by specific enzyme-linked
immunosorbent assay kits (Otsuka Pharmaceutical Co). Because
significant interindividual variability of cytokine
production by PBMC in response to LPS was observed,
cytokine production from two to five subjects was
measured (2 wells from each). None of the agents affected monocyte
viability, verified by staining with trypan blue.
Statistical Analyses
Because the amount of the cytokines produced was
different in each experiment, the effects of the drugs on
cytokine production was expressed as a percent response
compared with the control wells containing LPS. Statistical
analyses were performed by one-way ANOVA with multiple
comparisons by Fisher's protected least significant difference test.
All values are presented as the mean±SE. A value of
P<.05 was considered statistically significant.
| Results |
|---|
|
|
|---|
production was decreased by amiodarone in
a concentration-dependent manner. Compared with a stimulated control of
2.15±0.57 ng/mL, concentrations of 0.1, 1, and 10
µmol/L (n=10 each) decreased TNF-
by 70±15%, 61±13%,
and 54±10%, respectively (P<.05 at 1
µmol/L, P<.01 at 10 µmol/L versus
control; Fig 1
production in a concentration-dependent
manner. Compared with a stimulated control of 6.69±3.3 ng/mL,
quinidine concentrations of 0.1, 1, and 10 µmol/L (n=4
each) increased TNF-
by 117±10%, 131±7%, and 149±13%,
respectively (P<.05 and P<.01 at 1 and 10
µmol/L, respectively; Fig 1
at all concentrations (162±30%,
151±20%, and 147±33%, respectively; n=4 each). However, these
differences did not reach statistical significance.
|
IL-6 production was significantly inhibited by
amiodarone at all three concentrations (67±6%, 65±6%, and
66±3%; P<.0001) compared with a stimulated control value
of 2.1±0.4 ng/mL (Fig 2
).
Conversely, in comparison with a stimulated control of 1.7±0.2
ng/mL, disopyramide increased IL-6
production significantly (120±5%, 113±3%, and 122±5%,
respectively; P<.05) whereas quinidine and lidocaine had no
significant effect (Fig 2
).
|
IL-1ß in the presence of amiodarone was slightly decreased at
concentrations of 0.1 and 1 µmol/L (76±11% and 68±9%,
respectively, versus a stimulated control of 8.6±3.8 ng/mL) but
markedly increased at a concentration of 10 µmol/L
(228±72%; P<.05) (Fig 3
).
IL-1ß production was not significantly changed by quinidine,
disopyramide, or lidocaine.
|
| Discussion |
|---|
|
|
|---|
have
been reported in patients with chronic heart failure,14 15
and TNF-
has been reported to depress myocardial
contractility.16 17 18 19 Furthermore, TNF-
,
IL-1ß, and interferon-
have cytotoxic effects on cultured cardiac
myocytes.20 In addition to these humoral effects,
cytokines may activate cytotoxic T-cells, thereby
causing direct injury to the myocyte.21 IL-6 may also
exert a negative inotropic effect,16 and mice
overexpressing both IL-6 and IL-6 receptors have been reported to
develop cardiac hypertrophy.22 Other recent
observations suggest that growth abnormalities, which accompany
hypertrophy of the overloaded myocardium, may
play an important role in the deterioration of the condition of
patients with chronic heart failure.23
Recent studies from our laboratory14 have shown that
increased concentrations of circulating TNF-
are found more often in
patients with nonischemic than those with ischemic
heart failure. In our animal models of nonischemic heart
failure induced by viral myocarditis,24 25 plasma TNF-
concentration was increased in the blood, and exogenously given
antiTNF-
antibody improved both myocardial injury and survival of
the animals.26 Furthermore, in the same model, the
expression of TNF-
messenger RNA was increased in the acute stage
and persisted into the chronic stage,27 and
immunohistochemical analyses revealed that
endothelial cells and interstitial
macrophages were positive for TNF-
. These observations
suggest that TNF-
plays an important role in the pathogenesis of
nonischemic heart failure.
The reduced production of TNF-
and IL-6 by
amiodarone measured in the present study was in sharp
contrast to the effects produced by three other antiarrhythmic agents
and may explain the hemodynamic effects of
amiodarone noted in clinical studies. Therapeutic plasma
concentrations of amiodarone range between 0.5 and 2
µg/mL, which is equivalent to 0.87 to 3.1
µmol/L, within the range of concentrations used in these
experiments.
The mechanisms by which amiodarone modulates cytokine production remain to be clarified. The involvement of ion channels in T-lymphocyte activation and proliferation is well established.28 29 The involvement of K+ channels in lymphocyte activation and cytotoxic function has been reported recently with the use of the scorpion-derived peptide margatoxin, a specific K+ channel blocker in lymphocytes.30 Vesnarinone, which has been reported to reduce K+ current,31 inhibits the production of cytokines.10 Because amiodarone blocks the inward rectifier K+ channel,32 it may inhibit cytokine release by modulating ion channels. This hypothesis, if verified, may help in the development of more targeted pharmacological treatments of CHF.
Additional studies are necessary to confirm our findings using lymphocytes from patients with CHF. Our observations do not establish a direct connection between the effects of amiodarone on cytokines and its hemodynamic effects. Additional studies will be needed to examine this link in vivo in animal models, as well as by measuring cytokines in patients suffering from CHF who are treated with amiodarone.
| Selected Abbreviations and Acronyms |
|---|
|
| Acknowledgments |
|---|
Received April 16, 1997; revision received June 4, 1997; accepted June 10, 1997.
| References |
|---|
|
|
|---|
. Circ Res. 1990;67:68-77.
in the adult mammalian heart.
J Clin Invest. 1993;92:2303-2312.
antibody on the murine model
of viral myocarditis induced by encephalomyocarditis virus.
Circulation. 1994;89:846-851.This article has been cited by other articles:
![]() |
H. Tachikawa, M. Kodama, K. Watanabe, T. Takahashi, M. Ma, T. Kashimura, M. Ito, S. Hirono, Y. Okura, K. Kato, et al. Amiodarone Improves Cardiac Sympathetic Nerve Function to Hold Norepinephrine in the Heart, Prevents Left Ventricular Remodeling, and Improves Cardiac Function in Rat Dilated Cardiomyopathy Circulation, February 22, 2005; 111(7): 894 - 899. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Datta, T. Waghray, M. Torres, and S. Glusman Amiodarone Decreases Heat, Cold, and Mechanical Hyperalgesia in a Rat Model of Neuropathic Pain Anesth. Analg., January 1, 2004; 98(1): 178 - 184. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. C. Choo, B. Huiskes, J. Jones, S. Fabbri, L. A. Hawkins, K. Chatterjee, T. De Marco, and J. T. Heywood Amiodarone Rescue Therapy for Severe Decompensated Heart Failure Initially Unsuitable for {beta}-Blockers Journal of Cardiovascular Pharmacology and Therapeutics, September 1, 2003; 8(3): 187 - 192. [Abstract] [PDF] |
||||
![]() |
A. Deswal, N. J. Petersen, A. M. Feldman, B. G. White, and D. L. Mann Effects of Vesnarinone on Peripheral Circulating Levels of Cytokines and Cytokine Receptors in Patients With Heart Failure : A Report From the Vesnarinone Trial Chest, August 1, 2001; 120(2): 453 - 459. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. S. Filippatos, B. D. Uhal, H. Tsutsui, T. Ide, S. Kinugawa, A. Takeshita, and H. Utsumi Effects of Amiodarone on Heart Cells Response Circulation, November 14, 2000; 102 (20): e170 - e170. [Full Text] [PDF] |
||||
![]() |
A. M. Feldman, A. Combes, D. Wagner, T. Kadakomi, T. Kubota, Y. You Li, and C. McTiernan The role of tumor necrosis factor in the pathophysiology of heart failure J. Am. Coll. Cardiol., March 1, 2000; 35(3): 537 - 544. [Abstract] [Full Text] [PDF] |
||||
![]() |
M Tendera and H Wysocki TNF-{alpha} in patients with chronic failure is not only a proinflammatory cytokine Eur. Heart J., October 2, 1999; 20(20): 1445 - 1446. [PDF] |
||||
![]() |
S. Sasayama, A. Matsumori, and Y. Kihara New insights into the pathophysiological role for cytokines in heart failure Cardiovasc Res, June 1, 1999; 42(3): 557 - 564. [Full Text] [PDF] |
||||
![]() |
C. Kawai From Myocarditis to Cardiomyopathy: Mechanisms of Inflammation and Cell Death : Learning From the Past for the Future Circulation, March 2, 1999; 99(8): 1091 - 1100. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. R. Meldrum Tumor necrosis factor in the heart Am J Physiol Regulatory Integrative Comp Physiol, March 1, 1998; 274(3): R577 - R595. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. R. Wagner, C. McTiernan, V. J. Sanders, and A. M. Feldman Adenosine Inhibits Lipopolysaccharide-Induced Secretion of Tumor Necrosis Factor-{alpha} in the Failing Human Heart Circulation, February 17, 1998; 97(6): 521 - 524. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1997 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |